PAM - Pampa Energía S.A.
Founder and chairman Marcis Marcelo Mindlin acquired 287,916 shares for a $969,000 on June 26. The activity was executed in the open market and does not involve indirect entities or derivative instruments.
A Pampa Energy executive sold 555,000 shares of the company in the open market on June 3, 2026, generating a transaction value of $1.97 million at around $3.55 per share. The disposition was executed directly, with no shares held indirectly or through trusts; no derivative exercise was involved in this transaction.
Investors looking for stocks in the Utility - Electric Power sector might want to consider either Pampa Energia (PAM) or DTE Energy (DTE). But which of these two stocks offers value investors a better bang for their buck right now?
The mean of analysts' price targets for Pampa (PAM) points to a 38.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
GCO, PAM, OXY, CLDT and TGS stand out with attractive EV-to-EBITDA ratios and strong earnings outlooks.
Delinea has been recognized as a Growth Index Leader and Innovation Index Leader in the Frost Radar™: Privileged Access Management (PAM) 2026 report.
Pampa Energia is expanding power capacity and leveraging Argentina's electricity investments, backed by strong earnings growth, liquidity, and a diversified fleet.
Pampa Energia (PAM) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Investors looking for stocks in the Utility - Electric Power sector might want to consider either Pampa Energia (PAM) or DTE Energy (DTE). But which of these two stocks offers value investors a better bang for their buck right now?
The mean of analysts' price targets for Pampa (PAM) points to a 38% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Pampa Energia NYSE: PAM reported a sharp increase in first-quarter adjusted EBITDA, supported by record oil and gas production, the continued ramp-up of its Rincón de Aranda shale oil project and improved margins in power generation under Argentina's new electricity market framework.
Investors need to pay close attention to PAM stock based on the movements in the options market lately.
Palo Alto Networks Introduces Idira: the Next-Generation Identity Security Platform Built for the AI Enterprise PR Newswire
Stock News Discount chains gain share: Budget-conscious consumers are flocking to discounters, with Aldi adding 17 million U.S. customers in 2025 and planning 1
BUENOS AIRES, AR / ACCESS Newswire / May 6, 2026 / Pampa Energía S.A. (NYSE:PAM)(Buenos Aires Stock Exchange:PAMP), an independent energy company with active participation in Argentine oil, gas and electricity, announces the results for the quarter ended on March 31, 2026.
Pampa (PAM) possesses solid growth attributes, which could help it handily outperform the market.
Investors interested in stocks from the Utility - Electric Power sector have probably already heard of Pampa Energia (PAM) and Pinnacle West (PNW). But which of these two stocks presents investors with the better value opportunity right now?
GABAB PAM chronic cough candidate continued towards clinic after demonstrating robust anti-tussive activity in multiple disease models Continued to reposition dipraglurant mGlu5 NAM for brain injury recovery Entered option and collaboration agreement with Sinntaxis for exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recovery Regained rights to phase 2 mGlu2 PAM asset, ADX71149 Partner, Indivior advanced GABAB PAM substance use disorders program successfully through IND enabling studies Strategic investment in Stalicla SA, confirming commitment to advancing innovative treatments for neurological disorders Cash position of CHF 1.6 million at December 31, 2025 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 30, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its full-year 2025 financial results for the period ended December 31, 2025, and provided a corporate update.
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today encouraging preclinical data demonstrating antitussive activity of its GABAB positive allosteric modulator (PAM) candidate in a bleomycin (BLM)-induced idiopathic pulmonary fibrosis (IPF) exacerbated chronic cough model.
Low price-to-sales stocks like SCVL, AHKSY, APLE, PAM and FAF screen as undervalued picks, with notes on debt, cash flow and business momentum.